These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 27173950)

  • 1. The role of bortezomib in the treatment of acute lymphoblastic leukemia.
    Zahid MF
    Future Oncol; 2016 Aug; 12(16):1861-4. PubMed ID: 27173950
    [No Abstract]   [Full Text] [Related]  

  • 2. Bortezomib interferes with adhesion of B cell precursor acute lymphoblastic leukemia cells through SPARC up-regulation in human bone marrow mesenchymal stromal/stem cells.
    Iwasa M; Miura Y; Fujishiro A; Fujii S; Sugino N; Yoshioka S; Yokota A; Hishita T; Hirai H; Andoh A; Ichinohe T; Maekawa T
    Int J Hematol; 2017 May; 105(5):587-597. PubMed ID: 28044259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical analysis of bortezomib combined with chemotherapy for one case of refractory acute lymphocytic leukemia].
    Xu JJ; Hu XH; Shen YY
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):697-8. PubMed ID: 22339831
    [No Abstract]   [Full Text] [Related]  

  • 4. Switching to Bortezomib may Improve Recovery From Severe Vincristine Neuropathy in Pediatric Acute Lymphoblastic Leukemia.
    Joshi J; Tanner L; Gilchrist L; Bostrom B
    J Pediatr Hematol Oncol; 2019 Aug; 41(6):457-462. PubMed ID: 31233464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advancements of bortezomib in acute lymphocytic leukemia treatment.
    Du XL; Chen Q
    Acta Haematol; 2013; 129(4):207-14. PubMed ID: 23295437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib-associated demyelinating neuropathy--clinical and pathologic features.
    Thawani SP; Tanji K; De Sousa EA; Weimer LH; Brannagan TH
    J Clin Neuromuscul Dis; 2015 Jun; 16(4):202-9. PubMed ID: 25996966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.
    Houghton PJ; Morton CL; Kolb EA; Lock R; Carol H; Reynolds CP; Keshelava N; Maris JM; Keir ST; Wu J; Smith MA
    Pediatr Blood Cancer; 2008 Jan; 50(1):37-45. PubMed ID: 17420992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
    Janssen JM; Dorlo TPC; Niewerth D; Wilhelm AJ; Zwaan CM; Beijnen JH; Attarbaschi A; Baruchel A; Fagioli F; Klingebiel T; De Moerloose B; Palumbo G; von Stackelberg A; Kaspers GJL; Huitema ADR
    Clin Pharmacokinet; 2020 Feb; 59(2):207-216. PubMed ID: 31313068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB.
    Bastian L; Hof J; Pfau M; Fichtner I; Eckert C; Henze G; Prada J; von Stackelberg A; Seeger K; Shalapour S
    Clin Cancer Res; 2013 Mar; 19(6):1445-57. PubMed ID: 23357978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.
    Lü S; Chen Z; Yang J; Chen L; Gong S; Zhou H; Guo L; Wang J
    Exp Hematol; 2008 Oct; 36(10):1278-84. PubMed ID: 18562081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New antibodies for acute lymphocytic leukemia.
    Advani AS
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):547-9. PubMed ID: 25356581
    [No Abstract]   [Full Text] [Related]  

  • 12. Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for Fas-mediated apoptosis in human leukemic cells.
    Ottosson-Wadlund A; Ceder R; Preta G; Pokrovskaja K; Grafström RC; Heyman M; Söderhäll S; Grandér D; Hedenfalk I; Robertson JD; Fadeel B
    Mol Pharmacol; 2013 Jan; 83(1):245-55. PubMed ID: 23093495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute lymphocytic leukemia in children. A medical success story.
    Kelly KP
    Adv Nurse Pract; 2000 Apr; 8(4):57-8, 61-4, 94. PubMed ID: 11146951
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel treatments in acute lymphocytic leukemia.
    Stein AS
    Clin Adv Hematol Oncol; 2014 Apr; 12(4):212-4. PubMed ID: 25003350
    [No Abstract]   [Full Text] [Related]  

  • 15. Rituximab as therapy for acute lymphoblastic leukemia.
    Thomas DA
    Clin Adv Hematol Oncol; 2010 Mar; 8(3):168-71. PubMed ID: 20400931
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase I study of bortezomib in refractory or relapsed acute leukemias.
    Cortes J; Thomas D; Koller C; Giles F; Estey E; Faderl S; Garcia-Manero G; McConkey D; Ruiz SL; Guerciolini R; Wright J; Kantarjian H
    Clin Cancer Res; 2004 May; 10(10):3371-6. PubMed ID: 15161691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphoproteomics and bortezomib/dexamethasone-induced response in relapsed acute lymphoblastic leukemia.
    Brown RE; Bostrom B; Zhang PL
    Ann Clin Lab Sci; 2004; 34(2):203-5. PubMed ID: 15228234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric regimens for adult acute lymphoblastic leukemia.
    Stock W
    Clin Adv Hematol Oncol; 2009 Apr; 7(4):244-6. PubMed ID: 19521325
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in pregnancy.
    Mainor CB; Duffy AP; Atkins KL; Kimball AS; Baer MR
    J Oncol Pharm Pract; 2016 Apr; 22(2):374-7. PubMed ID: 25616656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acute monocytic leukemia as secondary neoplasia in a girl with acute lymphocytic leukemia].
    Rodríguez-Luis JC; Brito Barroso ML; de la Cruz-Moreno J; Munguira Aguado P; González-Azpeitia G; Domínguez Ortega F
    An Esp Pediatr; 1989 Apr; 30(4):289-92. PubMed ID: 2662843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.